JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

Piceatannol ameliorates the memory ability and cognitive behavior in Alzheimer's disease mice

  • 0Department of Neurology, Jilin Province Neuropsychiatric Hospital, Siping, China.
Neurological Research +

|

November 13, 2025

|

November 13, 2025

View abstract on PubMed

Summary

This summary is machine-generated.

Piceatannol (PIC) treatment improved cognitive function and reduced oxidative stress in a mouse model of Alzheimer

Area Of Science

  • Neuroscience
  • Pharmacology
  • Biochemistry

Background

  • Alzheimer's disease (AD) is a neurodegenerative disorder characterized by oxidative stress and cognitive decline.
  • Piceatannol (PIC), a natural polyphenol, has demonstrated antioxidant properties, but its efficacy in AD models requires further investigation.

Purpose Of The Study

  • To evaluate the therapeutic potential of different doses of Piceatannol (PIC) in an established mouse model of Alzheimer's disease (AD).
  • To assess the impact of PIC on oxidative stress markers and cognitive function in AD mice.

Main Methods

  • An Alzheimer's disease mouse model was induced using D-gal and AlCl3.
  • Sixty mice were divided into control, AD model, donepezil-treated, and three PIC-treated groups (low, medium, high dose).
  • Treatment with varying doses of PIC was administered for 35 days, followed by cognitive and biochemical assessments.

Main Results

  • Piceatannol treatment significantly reduced escape latency and increased platform crossings in AD mice, indicating improved cognitive function.
  • PIC administration elevated levels of antioxidant enzymes superoxide dismutase (SOD) and glutathione peroxidase (GSH-Px) while decreasing malondialdehyde (MDA) in AD mice.
  • The observed effects were dose-dependent, with the high-dose PIC group showing the most significant improvements.

Conclusions

  • Piceatannol demonstrates significant neuroprotective effects against oxidative stress and cognitive impairment in an Alzheimer's disease mouse model.
  • PIC treatment improved memory and cognition, attenuated oxidative tissue injury, and exhibited minimal organ toxicity in the studied AD model.

Keywords:

Related Concept Videos

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists 01:30

527

Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.

Alzheimer's Disease: Treatment 01:22

782

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...

Alzheimer's Disease: Overview 01:26

1.6K

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...